CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is advanced (spread) and standard treatments have not worked or are not suitable.
- Your tumor tests positive for MSLN (a protein on the cancer cell surface) on at least half of the cells, and also positive for PD-L1.
- You have adequate organ function (heart, lungs, liver, kidneys, bone marrow) as checked by your doctor.
- You have not had any prior therapy that targets MSLN, or any gene therapy or CAR-T cell therapy.
- You do not have active infections (like HIV, hepatitis B or C, or syphilis), autoimmune disease requiring immune-suppressing drugs, or serious heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a new type of CAR-T cell therapy called Fast CAR T cells for people with advanced solid tumors. It is designed for patients whose tumors have certain markers (mesothelin and PD-L1) and who have not responded to or cannot tolerate standard treatments.
This trial tests a new type of CAR-T cell therapy designed to target two proteins, CD73 and AXL, found on cancer cells. It is for people with advanced or metastatic solid tumors (like bile duct, pancreatic, lung, breast, head and neck, or gynecologic cancers) who have not responded to standard treatment or have no standard first-line therapy available.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.